Aljonaieh Khalid Ibrahim
Department of Anesthesia, College of Medicine, King Khalid University Hospital, King Saud University, Riyadh, Kingdom of Saudi Arabia.
Saudi J Anaesth. 2018 Jan-Mar;12(1):3-9. doi: 10.4103/sja.SJA_440_17.
The study aimed to test the effect of intraoperative intravenous (IV) lidocaine on the incidence of postextubation laryngospasm in adult patients.
The prospective randomized clinical trial was conducted at tertiary care hospital in Riyadh, between January and December 2012. Seventy-two patients undergoing laparoscopic cholecystectomy were randomly assigned to receive either placebo ( = 36) or IV lidocaine ( = 36), 1 mg/kg bolus after desflurane was discontinued. Laryngospasm was graded from 0 to 3 based on the absence or presence of signs and the severity of postextubation laryngospasm.
The study was terminated early by the data monitoring committee because of safety concerns due to an increased incidence of postextubation laryngospasm. Patient demographics were similar for both groups. The incidence of postextubation laryngospasm was 19.5% in the placebo group and 0% in the treatment (lidocaine) group; this difference was statistically significant ( = 0.017; 95% confidence interval, 4.6% to 36.0%).
The cause of laryngospasm in our study was most likely the rapid increase in the concentration of inspired desflurane, which might have caused airway irritation. Therefore, we believe that pretreating patients at risk of developing laryngospasm with IV lidocaine could be effective.
本研究旨在测试术中静脉注射利多卡因对成年患者拔管后喉痉挛发生率的影响。
这项前瞻性随机临床试验于2012年1月至12月在利雅得的一家三级护理医院进行。72例行腹腔镜胆囊切除术的患者被随机分为两组,分别接受安慰剂(n = 36)或静脉注射利多卡因(n = 36),在停用地氟醚后给予1 mg/kg的静脉推注。根据拔管后喉痉挛的体征有无及严重程度,将喉痉挛分为0至3级。
由于拔管后喉痉挛发生率增加,出于安全考虑,数据监测委员会提前终止了该研究。两组患者的人口统计学特征相似。安慰剂组拔管后喉痉挛的发生率为19.5%,治疗(利多卡因)组为0%;这一差异具有统计学意义(P = 0.017;95%置信区间,4.6%至36.0%)。
我们研究中喉痉挛的原因很可能是吸入地氟醚浓度的快速增加,这可能导致了气道刺激。因此,我们认为用静脉注射利多卡因对有发生喉痉挛风险的患者进行预处理可能是有效的。